SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

HETLIOZ

VNDA·Vanda Pharmaceuticals Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market since 2014. A potential DSWPD label expansion is at least 12-18 months away (sNDA submission and FDA review cycle ahead; no PDUFA date set).
Why 3/10
HETLIOZ is already approved and commercialized with no pending dated regulatory decision; the DSWPD sNDA submission is planned but has no scheduled PDUFA date, and the jet lag hearing outcome is not a hard dated binary. Per the rubric, an approved marketed drug with no imminent new regulatory decision scores 3-5, and the heavily generic-eroded revenue stream further caps the HETLIOZ-specific impact.
Actionable Insight BEARISH

Watch for Vanda's DSWPD sNDA submission timeline and any FDA feedback from planned discussions; also monitor the formal evidentiary hearing on the jet lag rejection. Neither has a fixed date, so HETLIOZ-specific binary catalysts are not imminent. Vanda's near-term value is more tied to the imsidolimab PDUFA (December 12 2026) and Fanapt commercial trends than to HETLIOZ.

Price Chart

Loading chart...

Executive Summary

HETLIOZ (tasimelteon) is Vanda Pharmaceuticals' FDA-approved melatonin receptor agonist for Non-24-Hour Sleep-Wake Disorder in blind adults and for nighttime sleep disturbances in Smith-Magenis Syndrome. The drug faces severe generic competition that has slashed its net product sales 66% year-over-year to $5.6 million in Q2 2026 (bouncing to $21.7M in Q3 on shipment timing). Two FDA rejections for a jet lag label expansion and a June 2026 formal hearing contesting that refusal add regulatory uncertainty. Positive Phase 3 results in Delayed Sleep-Wake Phase Disorder (DSWPD) announced Sept 29 2026 offer a potential lifeline, but an sNDA submission has no scheduled date. HETLIOZ is increasingly a minor revenue contributor versus Vanda's lead asset Fanapt.

How It Works

A melatonin receptor agonist, meaning it mimics the body's natural sleep hormone melatonin to help reset the internal body clock (circadian rhythm) to a 24-hour schedule. It selectively activates MT1 and MT2 receptors in the brain that regulate sleep-wake timing.

Trial Status

HETLIOZ is FDA-approved for two indications (Non-24-Hour Sleep-Wake Disorder in adults and nighttime sleep disturbances in Smith-Magenis Syndrome for ages 16+ capsules / ages 3-15 oral suspension). A Phase 3 study in Delayed Sleep-Wake Phase Disorder (DSWPD) met its primary endpoint in September 2026, and Vanda plans to discuss the data with the FDA and submit a supplemental NDA. The FDA rejected an sNDA for jet lag disorder in January 2026 (second rejection), and a formal evidentiary hearing on that refusal was granted in June 2026.

The Two-Sided Case

▲ Bull Case3
Positive Phase 3 DSWPD data (Sept 2026): 37.1-minute sleep-onset shift vs placebo, p=0.022, with 60% of treated patients advancing sleep by >=30 minutes vs 15% on placebo, supporting a potential new label expansion
Q3 2026 HETLIOZ revenue bounced to $21.7M (including $7M shipment timing) from $5.6M in Q2, partly reflecting order lumpiness that could persist
Analyst consensus remains bullish on VNDA overall: 9 Buy/Strong Buy vs 2 Hold, with mean price target $11.50 (198% upside from the $3.86 reference price)
▼ Bear Case3
Generic tasimelteon from Teva, Apotex, and MSN is already on the market, causing HETLIOZ sales to collapse 66% year-over-year in Q2 2026 to $5.6M; revenue erosion is structural, not temporary
Two FDA rejections for the jet lag indication (most recently Jan 2026) with a -14% 1-day stock decline; the formal hearing granted in June 2026 has an uncertain outcome
HETLIOZ is becoming a small part of Vanda's business (roughly 11% of Q2 revenue vs Fanapt at 71%), limiting any HETLIOZ-specific catalyst impact on the overall stock

Upcoming Catalysts

  • DSWPD sNDA submission to FDA (no date announced yet)
  • Outcome of formal FDA evidentiary hearing on jet lag disorder application (granted June 2026, status unclear)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vanda Pharmaceuticals Inc. 8-K VNDA ·Originating report

Sources · 5

Hover a chip for the title
1 en.wikipedia.org2 prnewswire.com3 fiercepharma.com4 tradingkey.com5 federalregister.gov